Morgan Stanley’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $50.1M | Buy |
1,338,531
+418,845
| +46% | +$15.6M | ﹤0.01% | 2220 |
|
|
2026
Q1 | $33.4M | Buy |
919,686
+150,860
| +20% | +$6.74M | ﹤0.01% | 2494 |
|
|
2025
Q4 | $35.8M | Buy |
768,826
+86,692
| +13% | +$3.86M | ﹤0.01% | 2404 |
|
|
2025
Q3 | $28.4M | Sell |
682,134
-77,888
| -10% | -$2.49M | ﹤0.01% | 2549 |
|
|
2025
Q2 | $21.9M | Buy |
760,022
+245,338
| +48% | +$7.58M | ﹤0.01% | 2707 |
|
|
2025
Q1 | $17.3M | Buy |
514,684
+9,644
| +2% | +$360K | ﹤0.01% | 2846 |
|
|
2024
Q4 | $25.8M | Sell |
505,040
-160,559
| -24% | -$8.98M | ﹤0.01% | 2510 |
|
|
2024
Q3 | $34M | Sell |
665,599
-173,026
| -21% | -$8.92M | ﹤0.01% | 2239 |
|
|
2024
Q2 | $37.6M | Buy |
838,625
+226,425
| +37% | +$10.5M | ﹤0.01% | 2020 |
|
|
2024
Q1 | $28.7M | Sell |
612,200
-36,051
| -6% | -$1.41M | ﹤0.01% | 2298 |
|
|
2023
Q4 | $23.1M | Buy |
648,251
+136,930
| +27% | +$4.2M | ﹤0.01% | 2546 |
|
|
2023
Q3 | $15.2M | Sell |
511,321
-234,838
| -31% | -$4.84M | ﹤0.01% | 2737 |
|
|
2023
Q2 | $13.4M | Buy |
746,159
+93,243
| +14% | +$1.86M | ﹤0.01% | 2883 |
|
|
2023
Q1 | $10.5M | Buy |
652,916
+500,328
| +328% | +$9.26M | ﹤0.01% | 3098 |
|
|
2022
Q4 | $2.79M | Buy |
152,588
+50,556
| +50% | +$891K | ﹤0.01% | 4232 |
|
|
2022
Q3 | $2M | Sell |
102,032
-37,584
| -27% | -$766K | ﹤0.01% | 4434 |
|
|
2022
Q2 | $2.6M | Buy |
139,616
+44,326
| +47% | +$885K | ﹤0.01% | 4332 |
|
|
2022
Q1 | $2.09M | Buy |
95,290
+57,312
| +151% | +$1.16M | ﹤0.01% | 4491 |
|
|
2021
Q4 | $1.08M | Sell |
37,978
-30,976
| -45% | -$764K | ﹤0.01% | 5015 |
|
|
2021
Q3 | $1.45M | Sell |
68,954
-113,043
| -62% | -$2.36M | ﹤0.01% | 4808 |
|
|
2021
Q2 | $3.43M | Sell |
181,997
-18,756
| -9% | -$330K | ﹤0.01% | 4163 |
|
|
2021
Q1 | $3.07M | Buy |
200,753
+15,011
| +8% | +$233K | ﹤0.01% | 3904 |
|
|
2020
Q4 | $2.62M | Buy |
185,742
+145,036
| +356% | +$2.02M | ﹤0.01% | 3916 |
|
|
2020
Q3 | $638K | Sell |
40,706
-173,115
| -81% | -$2.65M | ﹤0.01% | 4507 |
|
|
2020
Q2 | $3.75M | Buy |
213,821
+211,570
| +9,399% | +$3.61M | ﹤0.01% | 2968 |
|
|
2020
Q1 | $34K | Sell |
2,251
-15,156
| -87% | -$311K | ﹤0.01% | 5596 |
|
|
2019
Q4 | $437K | Sell |
17,407
-131
| -0.7% | -$2.49K | ﹤0.01% | 4997 |
|
|
2019
Q3 | $264K | Buy |
17,538
+16,249
| +1,261% | +$316K | ﹤0.01% | 4994 |
|
|
2019
Q2 | $32K | Sell |
1,289
-1,693
| -57% | -$41.9K | ﹤0.01% | 5776 |
|
|
2019
Q1 | $67K | Sell |
2,982
-9,201
| -76% | -$226K | ﹤0.01% | 5543 |
|
|
2018
Q4 | $365K | Sell |
12,183
-153
| -1% | -$4.31K | ﹤0.01% | 4993 |
|
|
2018
Q3 | $353K | Buy |
+12,336
| New | +$366K | ﹤0.01% | 5182 |
|
Other funds holding CRNX
FCM
DCM
JT
Morgan Stanley's CRNX Position: Q2 2026 in Review
Morgan Stanley increased its Crinetics Pharmaceuticals (CRNX) stake by 46% in Q2 2026, buying an estimated $15.6M and bringing the position to 1,338,531 shares worth $50.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2220.
Morgan Stanley first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Morgan Stanley held 1,338,531 shares of Crinetics Pharmaceuticals worth $50.1M as of Q2 2026.
- Morgan Stanley bought 418,845 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $15.6M.
- Crinetics Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2220 holding.
- Morgan Stanley first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.